GRIN Therapeutics is a life sciences company working to develop the investigational product radiprodil as a novel therapy for patients diagnosed with GRIN-related disorders. The company has initiated the Honeycomb phase 1 clinical trial to assess the safety and efficacy of radiprodil in the treatment of GRIN-related disorders.